We are live on ! Find out more
MREO

Mereo BioPharma
MREO

47 hedge funds and large institutions have $205M invested in Mereo BioPharma in 2020 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

438% more capital invested

Capital invested by funds: $38.1M → $205M (+$167M)

333% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 6

68% more funds holding

Funds holding: 28 → 47 (+19)

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

8.56% more ownership

Funds ownership: 4.57% → 13.13% (+8.6%)

Holders
47
Holders Change
+19
Holders Change %
+67.86%
% of All Funds
0.83%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
26
Increased
8
Reduced
6
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$15.1M
2
Citadel Advisors
Citadel Advisors
Florida
+$10.3M
3
SCM
Suvretta Capital Management
New York
+$6.89M
4
BC
Boxer Capital
California
+$5.5M
5
Alkeon Capital Management
Alkeon Capital Management
New York
+$4.85M

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$5.01M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$745K
3
MWNA
Marshall Wace North America
New York
-$467K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$301K
5
JG
Jefferies Group
New York
-$236K
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$577K +$404K +161,180 New
BFM
27
Boothbay Fund Management
New York
$458K -$14K -5,586 -4%
IC
28
Ikarian Capital
Texas
$416K -$125K -50,000 -4%
VF
29
Virtu Financial
New York
$215K +$150K +59,966 New
HSBC Holdings
30
HSBC Holdings
United Kingdom
$211K +$146K +58,217 New
PCM
31
Prelude Capital Management
New York
$188K +$132K +52,521 New
Jane Street
32
Jane Street
New York
$82K +$57.7K +23,038 New
NFC
33
Northeast Financial Consultants
Connecticut
$60K – – –
CL
34
CSS LLC
Illinois
$53K -$100K -40,038 -73%
WANY
35
Wealthspire Advisors (New York)
New York
$51K +$35.8K +14,276 New
SFI
36
Susquehanna Fundamental Investments
Pennsylvania
$40K +$28.1K +11,200 New
LC
37
Lindbrook Capital
California
$18K +$12.5K +5,000 New
UBS Group
38
UBS Group
Switzerland
$17K +$11.2K +4,456 +2,435%
Morgan Stanley
39
Morgan Stanley
New York
$15K -$3.26K -1,300 -24%
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
$7K -$301K -120,000 -98%
Bank of America
41
Bank of America
North Carolina
$6K – – –
SIA
42
Sit Investment Associates
Minnesota
$3K +$2.43K +970 New
Rockefeller Capital Management
43
Rockefeller Capital Management
New York
$1K – – –
Wells Fargo
44
Wells Fargo
California
$1K – – –
Osaic Holdings
45
Osaic Holdings
Arizona
$1K +$1.03K +410 New
RE
46
RBC Europe
United Kingdom
$659 +$461 +184 New
Point72 Asset Management
47
Point72 Asset Management
Connecticut
– -$745K -284,469 Closed
MWNA
48
Marshall Wace North America
New York
– -$467K -178,310 Closed
JG
49
Jefferies Group
New York
– -$236K -89,900 Closed
WP
50
WMS Partners
Maryland
– -$28K -10,642 Closed
1
2
3

MREO Hedge Fund Activity: Q4 2020 in Review

47 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q4 2020, worth a combined $205M — up 438% from $38.1M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new MREO positions and 6 closed out — a net gain of 20 holders — while 8 added to existing stakes and 6 trimmed.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $15.1M. The largest seller was Vivo Capital, cutting an estimated $5.01M.

  • 47 institutional investors held Mereo BioPharma (MREO) as of Q4 2020, up from 28 in Q3 2020.
  • Funds reported $205M of Mereo BioPharma stock for Q4 2020, up 438% quarter-over-quarter.
  • 26 funds opened new Mereo BioPharma positions in Q4 2020 and 6 closed out, a net change of +20 holders.
  • The largest Mereo BioPharma buyer in Q4 2020 was Baker Bros. Advisors, an estimated $15.1M added.
  • The largest Mereo BioPharma seller in Q4 2020 was Vivo Capital, an estimated $5.01M sold.

Based on aggregated 13F filings for Q4 2020.